판크레리파제 시장 조사 보고서(2026년)

In 2025, the global Pancrelipase market size was US$ 2,907 million and it will reach US$ 3,457 million in 2032, growing at CAGR of 2.99% between 2026 and 2032.

This report delivers a comprehensive overview of the global Pancrelipase market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pancrelipase. The Pancrelipase market size, estimates, and forecasts are provided in terms of sales volume (10 Billion LUE) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021-2032.

The report segments the global Pancrelipase market comprehensively. Regional market sizes by Release Type, by End User, by Dosage Form, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Pancrelipase manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Release Type, by End User, and by region.

Market Segmentation

By Company

• AbbVie
• Viatris
• Aimmune Therapeutics
• Abbott Laboratories
• BERLIN-CHEMIE
• Nordmark Pharma
• AVVA RUS
• Sun Pharma
• KRKA
• VIVUS
• Digestive Care
• Zentiva Pharma UK
• Essential Pharmaceuticals
• Biofarm SA
• OBNOVLENIE PFK
• Pharmbio Korea

Segment by Dosage Form

• Capsules
• Tablets
• Granules
• Powder

Segment by Release Type

• Delayed-Release
• Immediate-Release

Segment by Lipase Strength

• Low Strength
• Medium Strength
• High Strength

Segment by End User

• Cystic Fibrosis
• Chronic Pancreatitis
• Post-Surgical EPI
• Pancreatic Cancer
• Other

Consumption by Region

• North America
  • U.S.
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Argentina
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • U.A.E

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Release Type, by End User, by Dosage Form, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Provides a detailed analysis of the competitive landscape for Pancrelipase manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.

Chapter 3: Examines Pancrelipase sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.

Chapter 4: Analyzes segments by Dosage Form, detailing the size and growth potential of each segment to help readers identify "blue ocean" opportunities.

Chapter 5: Analyzes market segments by End User, covering the size and growth potential of each segment to help readers identify "blue ocean" opportunities in downstream markets.

Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.

Chapter 7: Reviews the industry value chain, including upstream and downstream segments.

Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.

Chapter 9: Summarizes the key findings and conclusions of the report.

Table of Contents

1 Pancrelipase Market Overview

• 1.1 Product Definition
• 1.2 Pancrelipase by Dosage Form
  • 1.2.1 Global Pancrelipase Market Value by Dosage Form: 2025 vs 2032
  • 1.2.2 Capsules
  • 1.2.3 Tablets
  • 1.2.4 Granules
  • 1.2.5 Other
• 1.3 Pancrelipase by Release Type
  • 1.3.1 Global Pancrelipase Market Value by Release Type: 2025 vs 2032
  • 1.3.2 Delayed-Release
  • 1.3.3 Immediate-Release
• 1.4 Pancrelipase by Lipase Strength
  • 1.4.1 Global Pancrelipase Market Value by Lipase Strength: 2025 vs 2032
  • 1.4.2 Low Strength
  • 1.4.3 Medium Strength
  • 1.4.4 High Strength
• 1.5 Pancrelipase by End User
  • 1.5.1 Global Pancrelipase Market Value by End User: 2025 vs 2032
  • 1.5.2 Cystic Fibrosis
  • 1.5.3 Chronic Pancreatitis
  • 1.5.4 Post-Surgical EPI
  • 1.5.5 Pancreatic Cancer
  • 1.5.6 Other
• 1.6 Global Pancrelipase Market Size Estimates and Forecasts
  • 1.6.1 Global Pancrelipase Revenue 2021-2032
  • 1.6.2 Global Pancrelipase Sales 2021-2032
  • 1.6.3 Global Pancrelipase Market Average Price (2021-2032)
• 1.7 Assumptions and Limitations

2 Pancrelipase Market Competition by Manufacturers

• 2.1 Global Pancrelipase Sales Market Share by Manufacturers (2021-2026)
• 2.2 Global Pancrelipase Revenue Market Share by Manufacturers (2021-2026)
• 2.3 Global Pancrelipase Average Price by Manufacturers (2021-2026)
• 2.4 Global Key Players of Pancrelipase, Industry Ranking, 2024 vs 2025
• 2.5 Global Key Manufacturers of Pancrelipase, Manufacturing Sites and Headquarters
• 2.6 Global Key Players of Pancrelipase, Product Types
• 2.7 Global Pancrelipase Market Competitive Situation and Trends
  • 2.7.1 Global Pancrelipase Market Concentration Rate
  • 2.7.2 The Top 5 and Top 10 Global Pancrelipase Players Market Share by Revenue
  • 2.7.3 Global Pancrelipase Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3 Global Pancrelipase Market Scenario by Region

• 3.1 Global Pancrelipase Market Size by Region: 2021 vs 2025 vs 2032
• 3.2 Global Pancrelipase Sales by Region: 2021-2032
  • 3.2.1 Global Pancrelipase Sales by Region: 2021-2026
  • 3.2.2 Global Pancrelipase Sales by Region: 2027-2032
• 3.3 Global Pancrelipase Revenue by Region: 2021-2032
  • 3.3.1 Global Pancrelipase Revenue by Region: 2021-2026
  • 3.3.2 Global Pancrelipase Revenue by Region: 2027-2032
• 3.4 North America Pancrelipase Market Facts & Figures by Country
  • 3.4.1 North America Pancrelipase Market Size by Country: 2021 vs 2025 vs 2032
  • 3.4.2 North America Pancrelipase Sales by Country (2021-2032)
  • 3.4.3 North America Pancrelipase Revenue by Country (2021-2032)
  • 3.4.4 U.S.
  • 3.4.5 Canada
• 3.5 Europe Pancrelipase Market Facts & Figures by Country
  • 3.5.1 Europe Pancrelipase Market Size by Country: 2021 vs 2025 vs 2032
  • 3.5.2 Europe Pancrelipase Sales by Country (2021-2032)
  • 3.5.3 Europe Pancrelipase Revenue by Country (2021-2032)
  • 3.5.4 Germany
  • 3.5.5 France
  • 3.5.6 U.K.
  • 3.5.7 Italy
  • 3.5.8 Russia
• 3.6 Asia Pacific Pancrelipase Market Facts & Figures by Region
  • 3.6.1 Asia Pacific Pancrelipase Market Size by Region: 2021 vs 2025 vs 2032
  • 3.6.2 Asia Pacific Pancrelipase Sales by Region (2021-2032)
  • 3.6.3 Asia Pacific Pancrelipase Revenue by Region (2021-2032)
  • 3.6.4 China
  • 3.6.5 Japan
  • 3.6.6 South Korea
  • 3.6.7 India
  • 3.6.8 Southeast Asia
• 3.7 Latin America Pancrelipase Market Facts & Figures by Country
  • 3.7.1 Latin America Pancrelipase Market Size by Country: 2021 vs 2025 vs 2032
  • 3.7.2 Latin America Pancrelipase Sales by Country (2021-2032)
  • 3.7.3 Latin America Pancrelipase Revenue by Country (2021-2032)
  • 3.7.4 Mexico
  • 3.7.5 Brazil
  • 3.7.6 Argentina
• 3.8 Middle East and Africa Pancrelipase Market Facts & Figures by Country
  • 3.8.1 Middle East and Africa Pancrelipase Market Size by Country: 2021 vs 2025 vs 2032
  • 3.8.2 Middle East and Africa Pancrelipase Sales by Country (2021-2032)
  • 3.8.3 Middle East and Africa Pancrelipase Revenue by Country (2021-2032)
  • 3.8.4 Turkey
  • 3.8.5 Saudi Arabia
  • 3.8.6 U.A.E

4 Segment by Dosage Form

• 4.1 Global Pancrelipase Sales by Dosage Form (2021-2032)
  • 4.1.1 Global Pancrelipase Sales by Dosage Form (2021-2026)
  • 4.1.2 Global Pancrelipase Sales by Dosage Form (2027-2032)
  • 4.1.3 Global Pancrelipase Sales Market Share by Dosage Form (2021-2032)
• 4.2 Global Pancrelipase Revenue by Dosage Form (2021-2032)
  • 4.2.1 Global Pancrelipase Revenue by Dosage Form (2021-2026)
  • 4.2.2 Global Pancrelipase Revenue by Dosage Form (2027-2032)
  • 4.2.3 Global Pancrelipase Revenue Market Share by Dosage Form (2021-2032)
• 4.3 Global Pancrelipase Price by Dosage Form (2021-2032)

5 Segment by End User

• 5.1 Global Pancrelipase Sales by End User (2021-2032)
  • 5.1.1 Global Pancrelipase Sales by End User (2021-2026)
  • 5.1.2 Global Pancrelipase Sales by End User (2027-2032)
  • 5.1.3 Global Pancrelipase Sales Market Share by End User (2021-2032)
• 5.2 Global Pancrelipase Revenue by End User (2021-2032)
  • 5.2.1 Global Pancrelipase Revenue by End User (2021-2026)
  • 5.2.2 Global Pancrelipase Revenue by End User (2027-2032)
  • 5.2.3 Global Pancrelipase Revenue Market Share by End User (2021-2032)
• 5.3 Global Pancrelipase Price by End User (2021-2032)

6 Key Companies Profiled

• 6.1 AbbVie
  • 6.1.1 AbbVie Company Information
  • 6.1.2 AbbVie Description and Business Overview
  • 6.1.3 AbbVie Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.1.4 AbbVie Pancrelipase Product Portfolio
• 6.2 Viatris
  • 6.2.1 Viatris Company Information
  • 6.2.2 Viatris Description and Business Overview
  • 6.2.3 Viatris Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.2.4 Viatris Pancrelipase Product Portfolio
• 6.3 Aimmune Therapeutics
  • 6.3.1 Aimmune Therapeutics Company Information
  • 6.3.2 Aimmune Therapeutics Description and Business Overview
  • 6.3.3 Aimmune Therapeutics Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.3.4 Aimmune Therapeutics Pancrelipase Product Portfolio
• 6.4 Abbott Laboratories
  • 6.4.1 Abbott Laboratories Company Information
  • 6.4.2 Abbott Laboratories Description and Business Overview
  • 6.4.3 Abbott Laboratories Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.4.4 Abbott Laboratories Pancrelipase Product Portfolio
• 6.5 BERLIN-CHEMIE
  • 6.5.1 BERLIN-CHEMIE Company Information
  • 6.5.2 BERLIN-CHEMIE Description and Business Overview
  • 6.5.3 BERLIN-CHEMIE Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.5.4 BERLIN-CHEMIE Pancrelipase Product Portfolio
  • 6.5.5 BERLIN-CHEMIE Recent Developments/Updates
• 6.6 Nordmark Pharma
  • 6.6.1 Nordmark Pharma Company Information
  • 6.6.2 Nordmark Pharma Description and Business Overview
  • 6.6.3 Nordmark Pharma Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.6.4 Nordmark Pharma Pancrelipase Product Portfolio
• 6.7 AVVA RUS
  • 6.7.1 AVVA RUS Company Information
  • 6.7.2 AVVA RUS Description and Business Overview
  • 6.7.3 AVVA RUS Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.7.4 AVVA RUS Pancrelipase Product Portfolio
  • 6.7.5 AVVA RUS Recent Developments/Updates
• 6.8 Sun Pharma
  • 6.8.1 Sun Pharma Company Information
  • 6.8.2 Sun Pharma Description and Business Overview
  • 6.8.3 Sun Pharma Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.8.4 Sun Pharma Pancrelipase Product Portfolio
• 6.9 KRKA
  • 6.9.1 KRKA Company Information
  • 6.9.2 KRKA Description and Business Overview
  • 6.9.3 KRKA Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.9.4 KRKA Pancrelipase Product Portfolio
  • 6.9.5 KRKA Recent Developments/Updates
• 6.10 VIVUS
  • 6.10.1 VIVUS Company Information
  • 6.10.2 VIVUS Description and Business Overview
  • 6.10.3 VIVUS Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.10.4 VIVUS Pancrelipase Product Portfolio
  • 6.10.5 VIVUS Recent Developments/Updates
• 6.11 Digestive Care
  • 6.11.1 Digestive Care Company Information
  • 6.11.2 Digestive Care Description and Business Overview
  • 6.11.3 Digestive Care Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.11.4 Digestive Care Pancrelipase Product Portfolio
  • 6.11.5 Digestive Care Recent Developments/Updates
• 6.12 Zentiva Pharma UK
  • 6.12.1 Zentiva Pharma UK Company Information
  • 6.12.2 Zentiva Pharma UK Description and Business Overview
  • 6.12.3 Zentiva Pharma UK Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.12.4 Zentiva Pharma UK Pancrelipase Product Portfolio
  • 6.12.5 Zentiva Pharma UK Recent Developments/Updates
• 6.13 Essential Pharmaceuticals
  • 6.13.1 Essential Pharmaceuticals Company Information
  • 6.13.2 Essential Pharmaceuticals Description and Business Overview
  • 6.13.3 Essential Pharmaceuticals Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.13.4 Essential Pharmaceuticals Pancrelipase Product Portfolio
  • 6.13.5 Essential Pharmaceuticals Recent Developments/Updates
• 6.14 Biofarm SA
  • 6.14.1 Biofarm SA Company Information
  • 6.14.2 Biofarm SA Description and Business Overview
  • 6.14.3 Biofarm SA Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.14.4 Biofarm SA Pancrelipase Product Portfolio
  • 6.14.5 Biofarm SA Recent Developments/Updates
• 6.15 OBNOVLENIE PFK
  • 6.15.1 OBNOVLENIE PFK Company Information
  • 6.15.2 OBNOVLENIE PFK Description and Business Overview
  • 6.15.3 OBNOVLENIE PFK Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.15.4 OBNOVLENIE PFK Pancrelipase Product Portfolio
• 6.16 Pharmbio Korea
  • 6.16.1 Pharmbio Korea Company Information
  • 6.16.2 Pharmbio Korea Description and Business Overview
  • 6.16.3 Pharmbio Korea Pancrelipase Sales, Revenue, and Gross Margin (2021-2026)
  • 6.16.4 Pharmbio Korea Pancrelipase Product Portfolio
  • 6.16.5 Pharmbio Korea Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

• 7.1 Pancrelipase Industry Chain Analysis
• 7.2 Pancrelipase Raw Material Supply Analysis
  • 7.2.1 Key Raw Materials
  • 7.2.2 Raw Materials Key Suppliers
• 7.3 Pancrelipase Production Mode & Process Analysis
• 7.4 Pancrelipase Sales and Marketing
  • 7.4.1 Pancrelipase Sales Channels
  • 7.4.2 Pancrelipase Distributors
• 7.5 Pancrelipase Customer Analysis

8 Pancrelipase Market Dynamics

• 8.1 Pancrelipase Industry Trends
• 8.2 Pancrelipase Market Drivers
• 8.3 Pancrelipase Market Challenges
• 8.4 Pancrelipase Market Restraints
• 8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

• 10.1 Methodology/Research Approach
  • 10.1.1 Research Programs/Design
  • 10.1.2 Market Size Estimation
  • 10.1.3 Market Breakdown and Data Triangulation
• 10.2 Data Source
  • 10.2.1 Secondary Sources
  • 10.2.2 Primary Sources
• 10.3 Author List
• 10.4 Disclaimer